PATENT CLAIM ANALYSIS

Application Number: 16240222
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-04
Patent Classification: ["424", "204100"]

Abstract:
The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.

Claim (Index 2):
The method of  claim 1 , wherein the La Crosse virus genome is derived from an LACV/human/1960 virus, an LACV/mosquito/1978 virus, or an LACV/human/1978 virus.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 99.0
- Lexical Diversity: 1.49091
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12593818', '13633633', '15850696', '10302547', '10371099']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7691465220213094
- 35 USC 102 Novelty (BERT): 0.7180972356906056
- Combined Prediction Score: 0.7640415933882391
- Mean Citation Score: 564.2183759999998
- Max Citation Score: 788.1304
- Similarity Product: 750.5227314769746

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test